Journal of Research in Medical Sciences1735-1995238201808251082410824EN20180820<table class="NormalTable"><tbody><tr><td width="550"><span class="fontstyle0">Background and Objective: </span><span class="fontstyle2">Myelosuppression is one of the frequent side e?ects of chemotherapy in breast cancer patients. Granulocyte?colony stimulating factor (G?CSF) and pegylated G?CSF are used for the prevention of neutropenia after chemotherapy. Pegylated G?CSF has longer half?life of action and can be used as a single dose in comparison to G?CSF. Te aim of this study is to compare the grade of cytopenia and side e?ects between G?CSF and biosimilar pegylated G?CSF in breast cancer patients treated with dose?dense chemotherapy. </span><span class="fontstyle0">Materials and Methods: </span><span class="fontstyle2">In the cross?over clinical trial study, 24 women with breast cancer were randomly divided into two groups and treated with dose?dense chemotherapy. Te frst group was treated with single dose of 6 mg<br />biosimilar pegylated G?CSF 24 h after the frst course of chemotherapy and the second course was followed by 300 </span><span class="fontstyle3">µ</span><span class="fontstyle2">g daily injection of G?CSF for 6 days. Te chemotherapy regimen was combination of doxorubicin 60 mg/m</span><span class="fontstyle2" style="font-size: 5pt;">2 </span><span class="fontstyle2">and cyclophosphamide 600 mg/m</span><span class="fontstyle2" style="font-size: 5pt;">2</span><span class="fontstyle2">. Te second group was treated with G?CSF after the frst course and pegylated G?CSF after the second course. Cell blood count (CBC) and side e?ects were evaluated 1 and 2 weeks after both courses of chemotherapy. </span><span class="fontstyle0">Results: </span><span class="fontstyle2">In this study, no signifcant carryover e?ect and treatment e?ect about the CBC parameters was found between pegylated G?CSF and G?CSF. Patients who were treated with biosimilar pegylated G?CSF had signifcantly higher side e?ects such as bone pain (</span><span class="fontstyle4">P </span><span class="fontstyle2">= 0.09) and gastrointestinal e?ects (</span><span class="fontstyle4">P </span><span class="fontstyle2">= 0.005)<br />in comparison to G?CSF. </span><span class="fontstyle0">Conclusion: </span><span class="fontstyle2">G?CSF and biosimilar pegylated G?CSF are e?ective in reducing cytopenia in breast cancer patients treated with dose?dense chemotherapy, but side e?ects induced by pegylated G?CSF (Pegagen) are higher.<br /></span></td></tr></tbody></table>http://jrms.mui.ac.ir/index.php/jrms/article/view/10824http://jrms.mui.ac.ir/index.php/jrms/article/download/10824/5658